epirubicin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 217 Diseases   226 Trials   226 Trials   3828 News 


«12...1112131415161718192021...4950»
  • ||||||||||  epirubicin / Generic mfg.
    Retrospective data, Review, Journal, HEOR:  Effects of Integrated Chinese Traditional Medicine and Conventional Western Medicine on the Quality of Life of Breast Cancer Patients: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Jan 18, 2022   
    For further analysis, chemotherapy with epirubicin exhibited higher quality of life than the chemotherapy without epirubicin among breast cancer patients [Z = 19.80, P < 0.05; Group 1: I  = 62.4%, P=0.070, SMD = 1.61; and Group 2: I  = 9.0%, P=0.359, SMD = 1.04]...Traditional Chinese medicine, when used in conjunction with the conventional Western medicine, could be an effective way in improving the quality of life and alleviating incidence of associated adverse symptoms such as gastrointestinal adverse reactions, value of tumor markers, and the incidence of traditional Chinese medicine syndrome. Further investigation of larger and methodologically sound trials with longer follow-up periods and appropriate comparison groups is needed.
  • ||||||||||  cisplatin / Generic mfg., epirubicin / Generic mfg.
    Journal:  Cancer drug screening with an on-chip multi-drug dispenser in digital microfluidics. (Pubmed Central) -  Jan 4, 2022   
    These findings demonstrate the reliability of the drug screening system with an on-chip drug dispenser. This system with fewer cancer cells, less drug consumption, a small footprint, and high scalability with regard to concentration could pave the way for drug screening on biopsied primary tumor cells for precision medicine or any concentration-related research.
  • ||||||||||  cisplatin / Generic mfg., epirubicin / Generic mfg.
    Journal, BRCA Biomarker, PARP Biomarker:  CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy. (Pubmed Central) -  Jan 1, 2022   
    Analysis of patient specimens revealed an abnormally high level of CRIP1 expression in GC tissues compared to that in the adjacent normal mucosa and a significant negative association between CRIP1 expression and survival time in patient cohorts with different types of solid tumors undergoing genotoxic treatments. In conclusion, our study suggests an essential function of CRIP1 in promoting HR repair and facilitating gastric cancer cell adaptation to genotoxic therapy.
  • ||||||||||  cisplatin / Generic mfg., epirubicin / Generic mfg.
    Journal:  Ru(II), Ir(III), Re(I) and Rh(III) based complexes as next generation anticancer metallopharmaceuticals. (Pubmed Central) -  Jan 1, 2022   
    Apart from the Ru(ii) complexes, a large amount of research has been carried out with Ir(iii), Re(i), and Rh(iii) based complexes, which exhibited promising anticancer activity. The present review reports various Ru(ii), Ir(iii), Re(i), and Rh(iii) based complexes for their anticancer activity based on their cytotoxicity profiles, biological targets and mechanism of action.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
    Journal:  Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells. (Pubmed Central) -  Dec 17, 2021   
    Upfront docetaxel did not improve chemotherapy activity or tolerability; these results suggest that upfront neoadjuvant treatment with anthracyclines remains a valid option. This study suggested that the transport characteristics are markedly different between EPI and DOX in HepG2 and A549 cells, and that intracellular accumulation is the predominant factor affecting the cytotoxicity of EPI and DOX in individual cells.
  • ||||||||||  Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
    Clinical, Journal:  Optimizing the timing of 3.6 mg Pegfilgrastim Administration for Dose-Dense Chemotherapy in Japanese Patients with Breast Cancer. (Pubmed Central) -  Dec 16, 2021   
    In the phase II feasibility study of DDCT (adriamycin+cyclophosphamide or epirubicin+cyclophosphamide followed by paclitaxel) for breast cancer, we investigated the feasibility, safety, neutrophil transition, and optimal timing of Peg treatment by administering Peg at days 2, 3, and 4 post-chemotherapy (P2, P3, and P4 groups, respectively)...The timing of Peg administration did not substantially affect the feasibility or safety of DDCT. Postoperative day 2 might be the optimal timing for DDCT.
  • ||||||||||  epirubicin / Generic mfg.
    Preclinical, Journal:  Effects of Combinatorial Ubiquitinated Protein-Based Nanovaccine and STING Agonist in Mice With Drug-Resistant and Metastatic Breast Cancer. (Pubmed Central) -  Dec 16, 2021   
    Here we enriched UPs from epirubicin (EPB)-induced multi-drug-resistant cancer stem-like breast cancer cell line (4T1/EPB) and tested the efficacy of α-AlO-UPs-4T1/EPB (short for UPs-4T1/EPB) as therapeutic vaccine alone and in combination with the stimulator of interferon genes (STING) agonist in mice with drug-resistant and metastatic breast cancer...Moreover, the cured mice were completely resistant against a subsequent rechallenge with the same tumor. Our study indicates that this novel combinatorial immunotherapy with UPs-4T1/EPB vaccine and STING agonist is effective in mice with drug-resistant and metastatic breast cancer.
  • ||||||||||  epirubicin / Generic mfg.
    Journal:  MiR-195 and Its Target SEMA6D Regulate Chemoresponse in Breast Cancer. (Pubmed Central) -  Dec 13, 2021   
    Our study indicates that this novel combinatorial immunotherapy with UPs-4T1/EPB vaccine and STING agonist is effective in mice with drug-resistant and metastatic breast cancer. microRNAs and their targets influence chemoresponse, allowing the identification of SEMA6D as a predictive marker for chemotherapy response that could be used to direct therapy or as a target in chemosensitisation strategies.
  • ||||||||||  AiTan (rivoceranib) / HLB Bio Group
    Journal, PD(L)-1 Biomarker, IO biomarker:  Anti-Tumor Effect of Apatinib and Relevant Mechanisms in Liposarcoma. (Pubmed Central) -  Dec 7, 2021   
    Apatinib and its combination with Epirubicin showed strong efficacy against liposarcoma both in vitro and in vivo. Apatinib might inhibit liposarcoma cell proliferation through the RRM2/PI3K/AKT/mTOR signaling pathway and downregulate PD-L1 via the TYMS/STAT3 signaling pathway.
  • ||||||||||  zolbetuximab (IMAB362) / Astellas
    Zolbetuximab + CAPOX versus CAPOX in first-line treatment of claudin18.2+/HER2– advanced/metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW phase 3 study. (In-Person Only | Level 1, West Hall; Poster Board - M3) -  Dec 4, 2021 - Abstract #ASCOGI2022ASCO_GI_176;    
    P2, P3
    2021) results showed prolonged survival with zolbetuximab + EOX (epirubicin, oxaliplatin, capecitabine) vs EOX in CLDN18.2+ advanced G/GEJ...2021) results showed promising antitumor activity with combination zolbetuximab + mFOLFOX6 (5-fluorouracil, folinic acid, oxaliplatin) in CLDN18.2+ advanced G/GEJ...Secondary endpoints: overall survival; objective response rate; duration of response; safety/tolerability, pharmacokinetics, and immunogenicity of zolbetuximab. As of September 22, 2021, 135 sites were open for screening and enrollment.
  • ||||||||||  cisplatin / Generic mfg., epirubicin / Generic mfg.
    Journal:  Structure based prediction of a novel GPR120 antagonist based on pharmacophore screening and molecular dynamics simulations. (Pubmed Central) -  Dec 2, 2021   
    100 ns all-atomic molecular dynamics (MD) simulations were performed on 9 small molecules identified and Cpd 9, (2-hydroxy-N-{4-[(6-hydroxy-2-methylpyrimidin-4-yl) amino] phenyl} benzamide) was predicted to be a small-molecule GPR120S antagonist. The conformational results from the collective all-atomic MD analysis provided structural information for further identification and optimisation of novel druggable inhibitors of GPR120S using this rational design approach, which could have future potential for anti-cancer drug development studies.
  • ||||||||||  vinorelbine tartrate / Generic mfg., paclitaxel / Generic mfg., epirubicin / Generic mfg.
    Clinical, Journal:  Drug resistance gene expression and chemotherapy sensitivity detection in Chinese women with different molecular subtypes of breast cancer. (Pubmed Central) -  Dec 1, 2021   
    The basal-like and HER2+ breast cancer primary cells showed chemosensitivities to paclitaxel and epirubicin with significant differences compared with luminal breast cancer primary cells (P < 0.05). The differential expression of drug resistance genes and the differential chemosensitivities of drugs in different molecular subtype of breast cancers suggested that individual treatment should be given for each type of breast cancer.
  • ||||||||||  cisplatin / Generic mfg., methotrexate / Generic mfg., epirubicin / Generic mfg.
    Clinical, Journal:  Neoadjuvant chemotherapy before radical cystectomy: why we must adhere? (Pubmed Central) -  Nov 29, 2021   
    Available evidence suggest better oncological outcomes for MIBC patients receiving neoadjuvant treatment before radical cystectomy. While MVAC remains the standard of care in cisplatin eligible patients, novel strategies are under development for cisplatin ineligible patients whereby immunotherapy seems to hold great promise.
  • ||||||||||  epirubicin / Generic mfg.
    Journal:  Epirubicin: Biological Properties, Analytical Methods, and Drug Delivery Nanosystems. (Pubmed Central) -  Nov 29, 2021   
    By contrast, high-performance liquid chromatography is a suitable method for detecting EPI in more complex matrices (e.g., plasm and urine) owing to its high sensitivity. This review summarizes physicochemical and pharmacokinetic properties of EPI, its application in drug delivery nanosystems, and the analytical methods employed in its quantification in different matrices, including blood, plasm, urine, and drug delivery nanosystems.
  • ||||||||||  goserelin acetate / Generic mfg., epirubicin / Generic mfg.
    Trial completion date, Trial primary completion date:  Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer (clinicaltrials.gov) -  Nov 29, 2021   
    P3,  N=234, Recruiting, 
    This review summarizes physicochemical and pharmacokinetic properties of EPI, its application in drug delivery nanosystems, and the analytical methods employed in its quantification in different matrices, including blood, plasm, urine, and drug delivery nanosystems. Trial completion date: Jun 2025 --> Dec 2026 | Trial primary completion date: Jan 2025 --> Jun 2026
  • ||||||||||  epirubicin / Generic mfg.
    Clinical, Journal:  POLRMT as a Novel Susceptibility Gene for Cardiotoxicity in Epirubicin Treatment of Breast Cancer Patients. (Pubmed Central) -  Nov 29, 2021   
    Individuals harbouring the risk allele had a decreased expression of POLRMT in heart tissue that may cause an impaired capacity to maintain a healthy mitochondrial population in cardiomyocytes under stressful conditions, as is treatment with epirubicin. This finding suggests a novel molecular mechanism involved in the development of AIC and may improve our ability to predict patients who are at risk.
  • ||||||||||  Yinuokai (orelabrutinib) / InnoCare, Biogen, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Enrollment change:  Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov) -  Nov 25, 2021   
    P3,  N=130, Recruiting, 
    Results on overall survival and further analysis investigating variation of tumour infiltrate according to patient risk stratification based on prognostic nomograms are in progresses and will be presented. N=100 --> 130
  • ||||||||||  pegylated liposomal doxorubicin / Generic mfg., cyclophosphamide / Generic mfg., epirubicin / Generic mfg.
    Trial completion date, Trial primary completion date:  A Study of Pegylated Liposomal Doxorubicin and Cyclophosphamide in Her2-negative Stage I and II Breast Cancer Patients (clinicaltrials.gov) -  Nov 23, 2021   
    P2,  N=254, Active, not recruiting, 
    iDFS is equal in both regimens, but tailoring dose-dense chemotherapy improved outcomes in HR+/HER2-, lobular cancer and patients ≤50 years. Trial completion date: May 2023 --> Oct 2022 | Trial primary completion date: Oct 2019 --> Oct 2022
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD)
    Trial completion, Trial completion date, Checkpoint inhibition, Checkpoint block:  Perioperative Chemo and Pembrolizumab in Gastric Cancer (clinicaltrials.gov) -  Nov 23, 2021   
    P2,  N=40, Completed, 
    Trial completion date: May 2023 --> Oct 2022 | Trial primary completion date: Oct 2019 --> Oct 2022 Recruiting --> Completed | Trial completion date: Sep 2022 --> Oct 2021
  • ||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
    New trial:  Neoadjuvant Treatment of Breast Cancer (clinicaltrials.gov) -  Nov 22, 2021   
    P=N/A,  N=300, Not yet recruiting,